What do the trials actually show for fibre, fluid, laxatives, movement, toileting and pelvic floor training?

What it is

The options studied for chronic constipation fall into groups: bulking fibres such as psyllium and wheat bran; fluid; physical activity; probiotics and synbiotics; osmotic laxatives (polyethylene glycol, lactulose, magnesium salts); stimulant laxatives (bisacodyl, sodium picosulphate, senna); stool softeners such as docusate; prescription secretagogues and prokinetics (lubiprostone, linaclotide, plecanatide, prucalopride); biofeedback for pelvic floor dyssynergia; and toileting posture and routine.

What the research says

The 2023 joint American Gastroenterological Association and American College of Gastroenterology guideline gives its strongest recommendations with moderate certainty to polyethylene glycol, bisacodyl or sodium picosulphate, linaclotide, plecanatide and prucalopride, and weaker conditional recommendations with low or very low certainty to fibre, magnesium oxide, lactulose, senna and lubiprostone. A Cochrane review found polyethylene glycol better than lactulose. Fibre supplements raise response and stool frequency, but almost all of that signal comes from psyllium, and polydextrose and galacto-oligosaccharides did not improve outcomes. Docusate appears no better than placebo. Probiotics show a modest pooled benefit for frequency, driven by Bifidobacterium lactis, with high heterogeneity and risk of bias, and no effect on stool consistency. Biofeedback improved response rates in a 2026 meta-analysis whose authors say small samples limit the conclusions. Squatting reduced straining and time in a small within-person comparison. Harms are real but mostly mild: fibre raises flatulence, and magnesium-containing laxatives have caused fatal hypermagnesaemia in older people with kidney impairment.

Evidence grade: Well established.

What goes wrong

In the adverse event data of this review, one psyllium trial reported abdominal pain in 18% of the fibre group and none on control, another recorded withdrawals for side effects, and a wheat bran trial recorded a withdrawal for "unbearable" abdominal pain. (Source 1)

• Meta-analysis, Low certainty.
• Size: adverse events reported in 12 studies including 1,089 participants.
• Who: adults with chronic constipation in randomised trials.
• How long: trial durations not stated in this passage.
• Result: psyllium: abdominal pain in 2 of the intervention group (18%) versus none on control in one trial; 3 intervention versus 5 control withdrawals for side effects in another psyllium trial; one wheat bran withdrawal for "unbearable" abdominal pain; 2 psyllium, 1 pectin and 2 GOS studies reported no serious adverse events.
• Funding: senior author reports an education grant from Alpro and research funding from the British Dietetic Association, Almond Board of California, International Nut and Dried Fruit Council and Nestec, plus consultancy for Puratos.

One study administering psyllium reported that 2 participants (18%) in the intervention group had abdominal pain, compared to none in the control group.

Fibre supplements significantly worsened flatulence severity compared with control in this review's pooled analysis. (Source 2)

• Meta-analysis, Low certainty.
• Size: 3 studies including 153 participants contributed the flatulence analysis.
• Who: adults with chronic constipation in randomised trials.
• How long: trial durations not stated in this passage.
• Result: flatulence severity SMD 0.80 (95% CI: 0.47, 1.13; P < 0.00001), no significant heterogeneity (I2 = 0%; P = 0.84); in subgroup analysis 2 inulin-type fructan studies SMD 0.79 (95% CI: 0.44, 1.14; P < 0.00001)
• Funding: senior author reports an education grant from Alpro and research funding from the British Dietetic Association, Almond Board of California, International Nut and Dried Fruit Council and Nestec, plus consultancy for Puratos.

Fiber significantly worsened flatulence severity compared to control (SMD: 0.80; 95% CI: 0.47, 1.13; P < 0.00001), and there was no significant heterogeneity (I2 = 0%; P = 0.84).

Magnesium oxide taken as a laxative has caused severe and sometimes fatal hypermagnesaemia in older people with impaired kidney function. (Source 3)

• Case series, Very low certainty.
• Size: four elderly patients, one of whom died.
• Who: patients over 65 with constipation and renal dysfunction, several unable to report symptoms because of stroke or dementia.
• How long: not stated.
• Result: four cases of symptomatic hypermagnesaemia after magnesium oxide, one with a lethal course; all older than 65 with renal dysfunction.
• Funding: not stated.

we present the cases of four elderly patients with constipation and symptomatic hypermagnesemia caused by MgO ingestion, one of which had a lethal course

What the evidence supports

A joint guideline from two gastroenterology societies rates polyethylene glycol and the stimulants bisacodyl or sodium picosulphate as strong recommendations on moderate certainty, and fibre, magnesium oxide, lactulose and senna as conditional recommendations on low or very low certainty. (Source 4)

• Official position, Moderate certainty.
• Size: guideline based on systematic reviews of randomised trials; trial counts not in this passage.
• Who: adults with chronic idiopathic constipation.
• How long: not applicable.
• Result: PEG: strong recommendation, moderate certainty. Bisacodyl or sodium picosulphate: strong recommendation, moderate certainty. Fibre: conditional, low certainty. Magnesium oxide: conditional, very low certainty. Lactulose: conditional, very low certainty. Senna: conditional, low certainty.
• Funding: American Gastroenterological Association and American College of Gastroenterology.

Recommendation 2: In adults with CIC, the panel recommends the use of PEG compared with management without PEG (strong recommendation, moderate certainty of evidence).

For prescription agents the guideline gives strong recommendations on moderate certainty to linaclotide, plecanatide and prucalopride, and only a conditional recommendation on low certainty to lubiprostone. (Source 5)

• Official position, Moderate certainty.
• Size: guideline based on systematic reviews of randomised trials.
• Who: adults with chronic idiopathic constipation who do not respond to over-the-counter agents.
• How long: not applicable.
• Result: linaclotide, plecanatide and prucalopride: strong recommendation, moderate certainty of evidence; lubiprostone: conditional recommendation, low certainty of evidence.
• Funding: American Gastroenterological Association and American College of Gastroenterology.

Recommendation 10: In adults with CIC who do not respond to OTC agents, the panel recommends the use of prucalopride over management without prucalopride (strong recommendation, moderate certainty of evidence).

A Cochrane review of all ten randomised trials found polyethylene glycol better than lactulose for stool frequency, stool form, abdominal pain relief and need for additional products. (Source 6)

• Systematic review, Certainty not rated.
• Size: ten randomised controlled trials.
• Who: adults and children with chronic constipation.
• How long: trial durations not stated in the conclusion passage.
• Result: no pooled numeric estimate in the quoted conclusion; superiority of polyethylene glycol reported for stool frequency per week, form of stool, relief of abdominal pain and need for additional products, in both adults and children except for abdominal pain.
• Funding: Cochrane review; funding not stated in the passage read.

The findings of our work indicate that Polyethylene glycol is better than lactulose in outcomes of stool frequency per week, form of stool, relief of abdominal pain and the need for additional products.

In the primary meta-analysis, fibre supplements increased stool frequency compared with control, with the trials disagreeing a great deal among themselves. (Source 7)

• Meta-analysis, Low certainty.
• Size: 14 randomised trials including 1,040 participants in the stool-frequency analysis.
• Who: adults with chronic constipation.
• How long: trial durations varied and are not stated in this passage.
• Result: SMD: 0.72 (95% CI: 0.36, 1.08; P = 0.0001), with considerable heterogeneity (I2 = 86%; P < 0.00001). This is the source of the figure the 2025 review quotes, and it is the interval to rely on: the review prints the upper bound as 10·8, which is impossible for an SMD of 0·72.
• Funding: not stated in the passage read.

Limit of this finding: The trials in this pooled result disagree strongly with one another - the paper's own heterogeneity figure is I2 = 86% - so the single pooled number hides a wide spread between studies. The same paper's risk-of-bias assessment reports that no study was at low risk of bias across all domains.

Fiber significantly increased stool frequency compared to control (SMD: 0.72; 95% CI: 0.36, 1.08; P = 0.0001); however, considerable heterogeneity was detected (I2 = 86%; P < 0.00001).

Psyllium is the fibre with the most consistent benefit across outcomes. (Source 8)

• Expert review, not systematic, Low certainty.
• Size: subgroup analyses within a meta-analysis of 16 RCTs and 1,251 people.
• Who: adults with chronic constipation.
• How long: 4 weeks or longer for the frequency benefit.
• Result: psyllium reported to give significantly higher response to treatment and stool frequency, softer stool consistency and lower straining versus control.
• Funding: author reports industry grants and consultancies as listed in the paper.

Psyllium supplements, a soluble and viscous fibre, was consistently shown to lead to significantly higher response to treatment and stool frequency, softer stool consistency and lower straining, compared to control

Across 13 cohort studies, higher physical activity was associated with a lower risk of constipation; this is an association rather than proof of cause, and the paper's headline confidence interval is printed in a form that cannot be correct. (Source 9)

• Systematic review, Low certainty.
• Size: 119,426 participants and 63,713 cases across 13 cohort studies.
• Who: adults in community cohorts.
• How long: cohort follow-up; durations not stated.
• Result: higher versus lower physical activity RR=0.69, with the paper printing its interval as "95% CI=0.88-0.83", which is impossible as printed; moderate versus lower activity RR=0.87 (95% CI=0.79-0.95); adherence to international activity guidelines RR=0.87 (95% CI=0.81-0.93); men and women collectively RR=0.66 (95% CI=0.55-0.80), described as a 34% lower risk.
• Funding: National Natural Science Foundation of China (82374610 and 82105038)

Limit of this finding: The paper prints the headline comparison as "RR=0.69; 95% CI=0.88-0.83". That interval cannot be right as printed: the lower figure is larger than the upper one, and 0.69 does not lie between them. This is an error in the published paper, not in our transcription. Read it as showing the direction of the association only - lower constipation risk in more active people - and do not treat 0.69 or that interval as a reliable size of effect. The paper's other intervals, such as RR=0.87 (95% CI=0.81-0.93) for meeting international activity guidelines, are internally consistent.

higher levels of PA were associated with a decreased risk of constipation compared with lower levels of PA

Biofeedback therapy increased response rates and weekly bowel movements in a 2026 meta-analysis, but the authors say small samples and methodological limits cap the confidence. (Source 10)

• Meta-analysis, Low certainty.
• Size: 19 randomised trials selected from 3,757 retrieved records.
• Who: adults with chronic constipation, including pelvic floor dyssynergia.
• How long: trial durations not stated in the abstract.
• Result: overall response rate RR 1.23 (95% CI 1.12, 1.34, P < 0.00001); weekly defecation frequency MD 1.60 (1.37, 1.82, P < 0.00001); constipation symptom score SMD -1.07 (-1.36, -0.79); quality of life score SMD -0.74 (-1.19, -0.29, P = 0.001); no significant difference in adverse events.
• Funding: Chengdu University of Traditional Chinese Medicine joint innovation fund and Sichuan Administration of Traditional Chinese Medicine.

the reliability of the conclusions is limited by the small sample sizes and methodological limitations of the included studies

What the evidence does not support

There is no evidence that drinking more water than public health recommendations improves constipation. (Source 11)

• Expert review, not systematic, Low certainty.
• Size: one RCT of 141 people is cited for water supplementation.
• Who: people with chronic constipation.
• How long: not stated.
• Result: one RCT in 141 people compared 2 l/day with ad libitum 1.1 l/day, both groups on a 25 g/day fibre diet, giving 4.2 (sd 1.3) versus 3.3 (sd 1.8) bowel movements per week, P < 0.001; the review nonetheless states that there is no evidence that increasing total water intake beyond public health recommendations improves constipation outcomes.
• Funding: author reports industry grants and consultancies as listed in the paper.

There is however no evidence suggesting that increasing total water intake beyond public health recommendations improves constipation outcomes.

Probiotic trials in this field are heterogeneous and at risk of bias, so the pooled benefit should be read cautiously. (Source 12)

• Meta-analysis, Very low certainty.
• Size: 34 RCTs in total.
• Who: adults with chronic constipation.
• How long: not stated.
• Result: high heterogeneity and risk of bias reported; insufficient evidence for synbiotics.
• Funding: academic authors.

Caution is needed when interpreting these results due to high heterogeneity and risk of bias amongst the studies.

Docusate, the common stool softener, appears no more effective than placebo. (Source 13)

• Systematic review, Low certainty.
• Size: review of the available clinical effectiveness evidence; trial count not stated in the key findings.
• Who: hospitalised patients and long-term care residents.
• How long: not stated.
• Result: no more effective than placebo for stool frequency or stool consistency; no apparent effect on abdominal cramps or on perceived completeness or difficulty of evacuation.
• Funding: Canadian Agency for Drugs and Technologies in Health.

Docusate appears to be no more effective than placebo for increasing stool frequency or softening stool consistency.

Where the evidence is mixed

The same guideline rates magnesium oxide and lactulose only conditionally, on very low certainty evidence. (Source 4)

• Official position, Very low certainty.
• Size: guideline based on systematic reviews of randomised trials.
• Who: adults with chronic idiopathic constipation.
• How long: not applicable.
• Result: magnesium oxide: conditional recommendation, very low certainty of evidence; lactulose (after failure or intolerance of over-the-counter therapies): conditional recommendation, very low certainty of evidence.
• Funding: American Gastroenterological Association and American College of Gastroenterology.

Recommendation 3: In adults with CIC, the panel suggests the use of magnesium oxide over management without magnesium oxide (conditional recommendation, very low certainty of evidence).

Fibre supplements improve response and stool frequency overall, but the benefit is carried by psyllium; polydextrose and galacto-oligosaccharides did not improve any outcome. (Source 8)

• Expert review, not systematic, Low certainty.
• Size: the meta-analysis described covers 16 RCTs and 1,251 people.
• Who: adults with chronic constipation.
• How long: subgroup benefit shown for treatment durations of 4 weeks or more.
• Result: response to treatment RR 1.48 (95% CI 1.17, 1.88; P = 0.001); doses above 10 g/day MD +1.6 bowel movements/week (95% CI 0.7, 2.5; P = 0.0004); 4 weeks or longer MD +1.3 (95% CI 0.6, 2.0; P = 0.0002); inulin-type fructans softened stool but did not change frequency; polydextrose and galacto-oligosaccharides improved nothing. For the pooled stool-frequency effect the review prints SMD 0·72, 95 % CI 0·36, 10·8; P = 0·0001, and an upper bound of 10·8 cannot be right for an SMD of 0·72 - the underlying meta-analysis prints 0.36, 1.08, which is recorded separately in this entry from the primary paper.
• Funding: author reports an education grant from Alpro, research grants from the Almond Board of California, the International Nut and Dried Fruit Council and Nestec, and consultancy for Puratos and Danone.

Limit of this finding: The review misprints one number. It gives the pooled stool-frequency effect as SMD 0·72 with a 95 % confidence interval of 0·36 to 10·8. An upper bound of 10·8 is impossible for a standardised mean difference of 0·72, and the meta-analysis the review is summarising (van der Schoot and colleagues, American Journal of Clinical Nutrition 2022) prints the interval as 0.36 to 1.08. Read 1.08 as the real upper bound and treat the review's 10·8 as a typesetting error; do not take 10·8 as a real estimate of how large the effect on stool frequency might be. The direction and significance of the result are not in doubt, and the response-to-treatment and subgroup numbers in the same passage match the primary meta-analysis.

However, polydextrose and galacto-oligosaccharide supplements did not improve any constipation outcomes

Probiotics gave a modest pooled improvement in response and stool frequency, driven by Bifidobacterium lactis, but did not change stool consistency, and synbiotics changed nothing. (Source 12)

• Meta-analysis, Low certainty.
• Size: 30 RCTs of probiotics and 4 of synbiotics; 647 versus 567 participants in the response analysis.
• Who: adults with chronic constipation.
• How long: trial durations not stated in the abstract.
• Result: response 369/647 (57%) versus 252/567 (44%), RR 1.28 (95% CI 1.07, 1.52, p = 0.007); stool frequency SMD 0.71 (0.37, 1.04, p < 0.00001); stool consistency SMD 0.26 (-0.03, 0.54, p = 0.08, not significant); synbiotics no effect on stool output or symptom scores.
• Funding: academic authors; the senior author reports industry grants and consultancies in related papers.

Probiotics did not impact stool consistency (SMD 0.26, 95% CI −0.03, 0.54, p = 0.08).

On long-term stimulant laxative use, a 2024 critical review reports reversible cell changes at supratherapeutic doses and no demonstrated damage to gut nerves or muscle, while noting the absence of formal long-term studies. (Source 14)

• Expert review, not systematic, Very low certainty.
• Size: critical narrative analysis of existing animal and human studies.
• Who: people using stimulant laxatives, including long term.
• How long: long term; no formal long-term studies identified for morphological change.
• Result: structural alterations to surface absorptive cells at supratherapeutic doses described as reversible and not clinically relevant; no formal long-term studies showing morphological change in enteric neural elements or smooth muscle with bisacodyl or sodium picosulphate; no convincing evidence of a link to colon cancer.
• Funding: not stated in the text we read; a reviewer should check the declaration of interests, as the authors publish widely on laxative products.

No formal long-term studies have demonstrated morphological changes in enteric neural elements or intestinal smooth muscle with bisacodyl or SPS in humans.

High mineral-content water raised the proportion of people who responded compared with low mineral-content water, but changed no individual symptom outcome. (Source 15)

• Expert review, not systematic, Low certainty.
• Size: a meta-analysis of four RCTs in 755 people, as described by the review.
• Who: people with chronic constipation.
• How long: not stated in the passage.
• Result: responder rate RR 1·47 (95 % CI 1·20, 1·81, P = 0·0002) for high versus low mineral-content water; no difference shown for stool frequency, global gut symptoms or abdominal pain/discomfort. This is a separate comparison from the plain-water supplementation trial reported in the next paragraph of the review, and the magnesium sulphate mechanism the review offers is an explanation, not a tested outcome.
• Funding: author reports an education grant from Alpro, research grants from the Almond Board of California, the International Nut and Dried Fruit Council and Nestec, and consultancy for Puratos and Danone.

A systematic review and meta-analysis of four RCTs in 755 people with chronic constipation showed that a significantly higher proportion of people responded to high mineral-content water, compared to low mineral-content water

Where the research disagrees

Whether long-term stimulant laxative use harms the colon

• Whorwell, Lange and Scarpignato, Therapeutic Advances in Gastroenterology 2024, critical narrative review of animal and human studies: These findings highlight the lack of evidence for the harmful effects of laxatives on the colon (Source 14)
• American Gastroenterological Association and American College of Gastroenterology, 2023 guideline, position based on GRADE review of randomised trials: the panel recommends the use of bisacodyl or sodium picosulphate short term or as rescue therapy (Source 4)

How much confidence fibre deserves as a treatment

• Dimidi, Proceedings of the Nutrition Society 2025, reporting a meta-analysis of 16 RCTs, narrative review reporting a meta-analysis: fibre supplements resulted in a significantly higher response to treatment (RR 1·48, 95 % CI 1·17, 1·88; P = 0·001) (Source 8)
• American Gastroenterological Association and American College of Gastroenterology, 2023 guideline, position based on GRADE review: the panel suggests the use of fiber supplementation over management without fiber supplements (conditional recommendation, low certainty of evidence) (Source 4)

A common belief, and what the research shows

The belief: A stool softener like docusate is the gentle first thing that works, and stimulant laxatives ruin your bowel.

What the research shows: The evidence points the other way on both counts. On docusate: "Docusate appears to be no more effective than placebo for increasing stool frequency or softening stool consistency." On stimulants, a 2024 critical review reports that "No formal long-term studies have demonstrated morphological changes in enteric neural elements or intestinal smooth muscle with bisacodyl or SPS in humans." - an absence of demonstrated harm rather than proof of safety.

Questions and answers

What are the actual treatment options, and which have the best evidence?

The joint 2023 American Gastroenterological Association and American College of Gastroenterology guideline gives strong recommendations on moderate certainty evidence to polyethylene glycol, to bisacodyl or sodium picosulphate short term or as rescue, and to linaclotide, plecanatide and prucalopride. Fibre, magnesium oxide, lactulose, senna and lubiprostone get weaker conditional recommendations on low or very low certainty evidence. That grading is the clearest summary of where the evidence is strong and where it is thin. (Source 4)

What do these things do in the body?

Osmotic agents such as polyethylene glycol, lactulose and magnesium salts hold water in the bowel; stimulants such as bisacodyl, sodium picosulphate and senna act on the bowel wall to prompt movement; bulking fibres such as psyllium change stool form and volume; prucalopride is a prokinetic and linaclotide and plecanatide are secretagogues; biofeedback retrains pelvic floor coordination rather than acting on stool. Where they have been compared head to head, polyethylene glycol outperformed lactulose. (Source 6)

Are laxatives good or bad for you?

The literature does not treat them as uniformly either. A 2024 critical review found no formal long-term studies demonstrating damage to gut nerves or muscle from bisacodyl or sodium picosulphate, and reported that changes seen at supratherapeutic doses were reversible. On the other side, magnesium-containing laxatives have caused fatal hypermagnesaemia in older people with kidney impairment, and fibre supplements measurably increase flatulence. Memios does not give medical advice. (Source 14)

If I wanted more of what works, what did the trials actually give people?

In the fibre meta-analysis, stool frequency improved at fibre doses above 10 g a day (MD +1.6 bowel movements per week) and with treatments lasting four weeks or more (MD +1.3). Water supplementation was tested at 2 litres a day against about 1.1 litres, both on a 25 g fibre diet. Probiotic trials used specific organisms, with Bifidobacterium lactis the one that showed an effect on frequency. These are what trials gave participants, not recommendations. (Source 8)

Which of these turned out not to work?

Docusate, the familiar stool softener, appears no more effective than placebo for stool frequency or consistency. Among fibres, polydextrose and galacto-oligosaccharides improved no constipation outcome. Probiotics did not change stool consistency, and synbiotics changed neither stool output nor symptom scores. And increasing total water intake beyond public health recommendations has no supporting evidence. (Source 13)

Why might a treatment that works in trials not work for a given person?

Two reasons show up in the literature. First, the mechanism has to match: biofeedback targets pelvic floor coordination, so it addresses a defecatory disorder rather than slow transit. Second, trial quality limits how far results generalise - the biofeedback meta-analysis says its conclusions are limited by small samples and methodological problems, and the fibre review reports that no study was at low risk of bias (which it abbreviates to RoB) across all domains. (Source 16)

Which whole foods or food-based options have evidence?

The food-based evidence is mainly fibre. A meta-analysis of 16 RCTs in 1,251 people found fibre supplements raised response to treatment (RR 1.48, 95% CI 1.17-1.88) and stool frequency, with psyllium the most consistent performer and inulin-type fructans softening stool without changing frequency. Two other fibres in the same analysis, polydextrose and galacto-oligosaccharides, improved nothing. (Source 8)

What if none of these are used at all?

The comparators in these trials are what happens without the treatment, and they are not zero: 44% of control participants in the probiotic trials responded, and control groups in the biofeedback trials also improved. That means untreated or differently treated constipation often improves somewhat by itself, which is part of why several guideline recommendations sit at low or very low certainty. (Source 12)

How would you know whether something is working?

The trials use a small set of measures: response to treatment, weekly bowel movement count, stool consistency, straining, symptom scores and quality of life. Biofeedback trials, for example, reported overall response rate, weekly defecation frequency, constipation symptom score and quality of life. There is no biological test of response; it is measured by counted bowel movements and rated symptoms. (Source 10)

Is it dangerous to use stimulant laxatives for a long time, or to become dependent on them?

A 2024 critical review of the evidence found no formal long-term human studies showing changes to gut nerves or smooth muscle with bisacodyl or sodium picosulphate, and no convincing link to colon cancer, and it noted that studies suggesting harm often failed to adjust for neurological disease, metabolic disorders and age. That is an absence of demonstrated harm rather than proof of safety, and the same guideline that recommends stimulants strongly frames them as short-term or rescue use. Memios reports this and does not advise. (Source 14)

Is magnesium a problem if someone's kidneys are not working well?

The case literature says yes. Four elderly patients with constipation and renal dysfunction developed symptomatic hypermagnesaemia after taking magnesium oxide, and one died. The authors note that serum magnesium is not usually checked in people prescribed it, and that people with chronic kidney disease and older people are the group at risk. (Source 3)

Does fibre ever make things worse?

It can cause symptoms. Pooling 3 trials in 153 people, fibre significantly worsened flatulence severity compared with control (SMD 0.80, 95% CI 0.47-1.13). In the adverse event data, one psyllium trial reported abdominal pain in 18% of the fibre group versus none on control, and a wheat bran trial recorded a withdrawal for unbearable abdominal pain. On the specific question of taking fibre without enough fluid, we found no trial evidence in the reviews we reached. (Source 1)

Does exercise help constipation?

The cohort evidence is consistent in direction: across 13 cohort studies with 119,426 participants, higher physical activity was associated with lower constipation risk, and meeting international activity guidelines carried RR 0.87 (95% CI 0.81-0.93). These are observational associations, so they show that more active people report less constipation, not that exercise treats it. The AGA-ACG guideline addressed drugs rather than exercise. (Source 9)

Does biofeedback help pelvic floor problems?

A 2026 meta-analysis of 19 randomised trials found biofeedback raised overall response (RR 1.23, 95% CI 1.12-1.34) and weekly bowel movements (MD 1.60, 95% CI 1.37-1.82), and improved symptom and quality of life scores, with no significant difference in adverse events. The authors themselves caution that small sample sizes and methodological limitations in the included trials limit how far those conclusions can be trusted. (Source 10)

References

1. The American Journal of Clinical Nutrition. The Effect of Fiber Supplementation on Chronic Constipation in Adults: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2022. PMID 35816465, DOI 10.1093/ajcn/nqac184. Read the source
2. The American Journal of Clinical Nutrition. The Effect of Fiber Supplementation on Chronic Constipation in Adults: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2022. PMID 35816465, DOI 10.1093/ajcn/nqac184. Read the source
3. CEN Case Reports. Severe hypermagnesemia induced by magnesium oxide ingestion: a case series. 2019. PMID 30136128, DOI 10.1007/s13730-018-0359-5. Read the source
4. Gastroenterology (American Gastroenterological Association and American College of Gastroenterology). American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation. 2023. PMID 37211380, DOI 10.1053/j.gastro.2023.03.214. Read the source
5. Gastroenterology (American Gastroenterological Association and American College of Gastroenterology). American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation. 2023. PMID 37211380, DOI 10.1053/j.gastro.2023.03.214. Read the source
6. Cochrane Database of Systematic Reviews. Lactulose versus Polyethylene Glycol for Chronic Constipation. 2010. PMID 20614462, DOI 10.1002/14651858.CD007570.pub2. Read the source
7. The American Journal of Clinical Nutrition. The Effect of Fiber Supplementation on Chronic Constipation in Adults: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2022. PMID 35816465, DOI 10.1093/ajcn/nqac184. Read the source
8. Proceedings of the Nutrition Society. Dietary management of chronic constipation: a review of evidence-based strategies and clinical guidelines. 2025. DOI 10.1017/S0029665125100694. Read the source
9. Journal of Global Health. Physical activity and constipation: A systematic review of cohort studies. 2024. DOI 10.7189/jogh.14.04197. Read the source
10. Frontiers in Medicine. Efficacy of biofeedback therapy for chronic constipation in adults: a systematic review and meta-analysis of randomized controlled trials. 2026. PMID 42292261, DOI 10.3389/fmed.2026.1759161. Read the source
11. Proceedings of the Nutrition Society. Dietary management of chronic constipation: a review of evidence-based strategies and clinical guidelines. 2025. DOI 10.1017/S0029665125100694. Read the source
12. Clinical Nutrition. Probiotics and synbiotics in chronic constipation in adults: A systematic review and meta-analysis of randomized controlled trials. 2022. PMID 36372047, DOI 10.1016/j.clnu.2022.10.015. Read the source
13. Canadian Agency for Drugs and Technologies in Health (CADTH), NCBI Bookshelf. Dioctyl Sulfosuccinate or Docusate (Calcium or Sodium) for the Prevention or Management of Constipation: A Review of the Clinical Effectiveness. 2014. Read the source
14. Therapeutic Advances in Gastroenterology. Review article: do stimulant laxatives damage the gut? A critical analysis of current knowledge. 2024. PMID 38887508, DOI 10.1177/17562848241249664. Read the source
15. Proceedings of the Nutrition Society. Dietary management of chronic constipation: a review of evidence-based strategies and clinical guidelines. 2025. DOI 10.1017/S0029665125100694. Read the source
16. The American Journal of Clinical Nutrition. The Effect of Fiber Supplementation on Chronic Constipation in Adults: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2022. PMID 35816465, DOI 10.1093/ajcn/nqac184. Read the source